NEW YORK, NY--(Marketwired - Aug 28, 2013) - As Nuvilex, Inc. (
Another clinical trial, another big pharmaceutical company, and another positive outcome for Nuvilex shareholders as the company once again produces better clinical trials data than the competition. Incyte investors rewarded the company's work with a 30% increase in its share price.
So, what is Nuvilex truly worth considering it's currently priced at less than $0.135 per share and its mid-phase data is better than any data produced by Incyte, Celgene, Infinity Pharmaceuticals, and even Eli Lilly, whose pancreatic cancer drug, Gemzar (gemcitabine), is the industry's "gold standard" and the only drug approved by the FDA as a single agent for the treatment of advanced, inoperable pancreatic cancer.
In commenting on Incyte's clinical trial results, Nuvilex's COO, Dr. Gerry Crabtree, stated, "The excitement engendered within the investment community upon publication of Incyte's mid-phase clinical trial data, as manifested by a 30% increase in that company's share price, serves to add impetus to all of us at Nuvilex in our pursuit of further clinical studies with our pancreatic cancer treatment. The fact that data such as that from Incyte's trial do not appear to surpass that obtained in our mid-phase clinical trials, only reinforces our belief that in the future, our treatment will help those who suffer from advanced pancreatic cancer, one of the deadliest and most difficult-to-treat forms of the disease."
Let's compare Nuvilex to the latest company releasing pancreatic cancer clinical trials results:
Continue Reading at: www.stockmarketmediagroup.com/features
About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Reports, CEO Interviews and Feature Articles. For more information: www.stockmarketmediagroup.com